What is Trastuzumab 440mg Injection Trasturel and how does it work?
Trastuzumab 440mg Injection Trasturel is a drug that is used to treat cancers of the breast, stomach, and oesophagus. This medicine is used to treat cancers that produce an excessive amount of a chemical known as HER2 protein. Trastuzumab is a monoclonal antibody, which means it belongs to a class of drugs called monoclonal antibodies.
What is a biosimilar to trastuzumab?
Trastuzumab (Herceptin) is a medication that targets the HER2 receptor. It’s used to treat HER2-positive breast tumors that are both early and metastatic. Trastuzumab biosimilars can be used to treat both early and advanced HER2-positive breast tumors.
Trastuzumab is a type of chemotherapy.
Trastuzumab is a monoclonal antibody that is used to treat metastatic (spread) breast cancer. It works against cancers that have an overabundance of the HER2/neu protein. as part of an adjuvant chemotherapy regimen for lymph-node-positive, HER2/neu protein-positive breast cancer patients. Gastric (stomach) cancer treatment
What are the Trastuzumab 440mg Injection Trasturel side effects?
- infection congestive heart failure, sleeplessness
- cough and rash are the most prevalent adverse effects found in the treatment of metastatic breast cancer (based on intravenous trastuzumab).
- For additional information on the benefits and hazards of HERCEPTIN HYLECTA, speak with a healthcare practitioner.
For more details Click Here.
Trastuzumab 440mg Injection Trasturel is an antibody, right?
Trastuzumab is a humanized monoclonal antibody that interacts with HER2’s extracellular domain IV. In 1998, the Food and Drug Administration (FDA) approved the first anti-HER2 antibody, trastuzumab, for the treatment of patients with HER2-overexpressed metastatic breast cancer.
What is the efficacy of Trastuzumab 440mg Injection Trasturel?
The addition of trastuzumab to chemotherapy enhanced 10-year survival from 75.2 percent to 84 percent in a 2014 study of over 4,000 patients, leading to a 37 percent relative improvement in overall survival. l. Over a 10-year period, the disease-free survival rate climbed from 62.2 percent to 73.7 percent. All patient groupings reaped the benefits.
Trastuzumab Injection belongs to what drug class?
Trastuzumab belongs to the monoclonal antibody class of drugs. It works by halting the growth of cancer cells.
Is trastuzumab considered a protein?
Trastuzumab is an anti-human epidermal growth factor receptor 2 protein monoclonal antibody that is used to treat HER2-positive breast, gastroesophageal, and gastric cancers.